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Summary
Aim: The goal of this study was to determine whether or not the intraarticular administration of hyaluronic acid can improve functional
parameters, such as isokinetic muscle strength or total work and clinical test results in patients with osteoarthritis (OA) of the knee.
Method: As part of a prospective, controlled study 43 patients with osteoarthritic changes of both knees (radiographic Kellgren stage II–III)
were followed in a right/left comparison. The influence of intraarticularly injected hyaluronic acid (20 mg hyaluronic acid/2 ml Hyalart®) on
functional and clinical parameters was analysed. We used the isokinetic system Cybex 600 for measuring maximal isokinetic muscle strength
and total work. A total of 20 males and 23 females fulfilled the inclusion criteria with an age between 55–78 years and underwent five
injections of hyaluronic acid (one injection per week). The injected knee represented the treatment group, while the contralateral knee served
as the control.
Results: The maximum peak torque of the knee extensors in the treatment group was measured between 57±26.15/32.33±19.63 Nm prior
to the injections and 77.17±32.54/47.83±21.43 Nm following the hyaluronic acid therapy (P<0.01). The analysis of the knee flexors at
angular velocities of 60°/s and 180°/s revealed values of 40.44±21.58/22.89±16.64 Nm and 53.55±24.26/34.05±17.37 Nm (P<0.01)
respectively. The evaluation of the total work of the knee flexors and extensors revealed a significant difference (P<0.01) between the
treatment and control group. The Lequesne score was reduced from 13.57±1.88 prior to the injections to 7.94±2.53 after the treatment
(P<0.01). The pain score was documented with the help of a visual analog scale. The VAS values were reduced at rest from 3.83±1.72 cm
to 1.36±1.42 cm and during weight bearing from 7.57±1.34 cm to 3.75±1.32 cm in the treatment group (P<0.01).
Conclusions: This controlled prospective clinical trial confirmed that 5 weekly intraarticular injections of HA (Hyalart®) in patients with OA of
the knee provide pain relief and functional improvements. © 2002 OsteoArthritis Research Society International. Published by Elsevier
Science Ltd. All rights reserved.
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Osteoarthritis (OA) or degenerative joint disease is the
most frequent joint disease known to man1. The treatment
of OA consists of pain reduction, modification of activities of
daily living and improvement of joint function2. Prior to
surgical management of the disease, which is expensive
and not risk-free, all other treatment options such as
medication and physical therapy should be fully exploited.
In the treatment protocol presented by Creamer and
Hochberg in Lancet 1997, hyaluronic acid plays an
important role3.
Hyaluronic acid represents one of the main components
of synovial fluid and is a polysaccharide consisting of
N-acetyl-D glucosamine and D-glucuronic acid. Hyaluronic
acid contributes to the elasticity and viscosity of synovial
fluid, and thus hyaluronans are used for the viscosupple-
mentation of joints4. Hyaluronic acid is produced by
chondrocytes and fibroblasts in the synovial lining (type-B-
cells)5.680Changes documented as part of OA include the reduc-
tion of viscoelastic properties of the hyaluronic acid sec-
ondary to reduced molecular weight, as well as a reduction
of its intraarticular concentration6–8. A number of controlled
studies have documented the therapeutic value of intraar-
ticular applicatoins of hyaluronic acid9–15. These studies
relied on pain relief (visual analog scale), knee function
(Lequesne or WOMAC score) as well as range of motion of
the affected joint as parameters for the effectiveness
of such a treatment.
The pain and consequent modification of activities fre-
quently lead to a reduced activity level. This can lead to a
weakening of the quadriceps and hamstring muscles with a
secondary increase of instability and joint degeneration. To
measure muscle strength, the use of isokinetic testing has
become widespread16,17. These tests are frequently used
as a diagnostic tool, as well as to document disease
progression and treatment effect in patients with muscle or
joint disorders18,19.
The aim of this study was to determine the efficacy of a
series of five intraarticular applications of hyaluronic acid
(Hyalart®) in patients with bilateral OA of the knee. Func-
tional parameters including isokinetic muscle strength or
total work, pain as documented via visual analog scale and
Lequesne score were evaluated.
Osteoarthritis and Cartilage Vol. 10 No. 9 681Material and methods
PATIENTS
Inclusion criteria
• Adults of both genders with a minimum age of 50 years.
• OA of both knees.
• Radiographic changes equivalent to Kellgren stage II–III
bilaterally.
• Symptomatic gonarthrosis for a minimum of 12 months.
• Pain level during weight bearing on the VAS of a
minimum of 4 cm bilaterally.
• To avoid larger differences between both affected knee
joints, the Lequesne score during the initial evaluation
may not differ by more than ±2 points in the total value.
Exclusion criteria
• Patients who do not meet all inclusion criteria.
• Neurological deficits in the lower extremities.
• The following underlying diseases were excluded:




— axis deviation of >15° varus or valgus malalignment
— ligamentous instability
— previous fractures of the joint
— arthroscopic surgery on the knee in the previous 12
months.
• Intraarticular injections of the knee joint in the 3 months
prior to the study.TRIAL DESIGN
The study was a prospective clinical trial carried out in
accordance with the principles of the Declaration of
Helsinki. Only patients with radiographically documented
bilateral degenerative joint disease of the knee were
included in this study20.
The treatment group had to receive an intraarticular
injection of 20 mg hyaluronic acid (Hyalart®, Bayer AG,
Leverkusen, Germany) weekly up to a total number of five
injections in the knee, which was randomized to treatment.
The control group received no treatment.
An intake of analgesics or non-steroidal antiinflammatory
drugs was to be avoided. Only paracetamol (500 mg) was
permitted as pain medication. Administration of paraceta-
mol 8 h before control assessment was prohibited. Physical
therapy was not carried out during the study period.
The patients that fulfilled the inclusion criteria without
presenting with an exclusion criteria were entered into a
randomization scheme for the administration of hyaluronic
acid into the right or left knee. A stratification was carried
out regarding the more impaired knee (right stratum 1; left
stratum 2). The injected knee was entered into the treat-
ment group, while the contralateral, untreated knee was
included in the control group. The stratification was carried
out based on the results of the primary evaluation of both
knees. In case a more impaired knee could not be defined
via objective criteria, the patient’s subjective view was
taken into account.CLINICAL ASSESSMENT
The clinical assessment was documented by the same
investigator for every patient prior to the first administration
of hyaluronic acid and after 5 weeks. A different physician
carried out the actual intraarticular injection of the
hyaluronic acid.
The clinical assessment included the following criteria:
(1) Evaluation of knee function. The Lequesne score
takes pain, maximal walking distance and the activi-
ties of daily living into account21. An independent
evaluation of each knee is possible, maximum point
score is 26.
(2) Isokinetic test. The evaluation was carried out with a
Cybex 6000 system (Cybex, Ronkonkoma, U.S.A.)
utilizing various velocities and repetitions (60°/s/5R,
90°/s/10R, 120°/s/12R, 150°/s/15R, 180°/s/20R). The
patient was placed in a seated position with 90° of hip
flexion. The degree of freedom of the knee was
restricted to extension/flexoion of 0–0–90°. A break of
2 min was granted between sets. From the retrieved
data the maximum work load (J) of all sets and the
maximum peak torque (Nm) at 60°/s and 180°/s were
determined. The maximum peak torque (Nm) was
defined as the maximum force produced by the tested
musculature at the various velocities.
(3) Pain intensity (visual analog scale). The patients were
asked to document their pain levels at rest, as well
as during weight bearing in accordance with the
Huskisson scale of 0 to 10 cm22.
The clinical data, isokinetic test, Lequesne score, and
VAS were obtained 1 day prior to the first injection. In the
following weeks, the next four intraarticular administraitons
were carried out. One week after the final injection, the
complete clinical assessment was repeated.STATISTICAL ANALYSIS
All the retrieved data was subjected to a descriptive
statistical analysis. The primary evaluation analysed the
treatment efficacy in accordance with the original intention-
to-treat. The data of all patients entering the study was
considered to be randomized. The comparison was carried
out between the treatment and non-treatment groups. A
paired t-test was applied. The level of significance was
fixed as =0.05. The statistic program SAS 6.10 (SAS
Institute, Inc., Cary, North Carolina) was used in the data
analysis.Results
A total of 43 patients (20 men; 23 women) fulfilled the
inclusion criteria and consented to take part in this study.
The average age was documented as 67.0 years (range
55–78). The average height and weight of the patients was
found to be 170±8 cm and 79±17 kg.
In the treatment group 24 knees were classified as the
more impaired knees and 19 knees as less impaired knees
by the patients. Naturally, in the control group the reversed
distribution was found (19 more; 24 less impaired knees).
In the hyaluronic acid treatment group 20 knees were
classified as Kellgren II and 23 as Kellgren III. In compari-
son, the control group included 26 knees documented as
Kellgren II and 17 as Kellgren III.
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reduction in the Lequesne score from 13.57±1.88 to
7.94±2.53 (P<0.01) at final follow-up. The untreated con-
trol group showed no significant change in the point score
(Fig. 1).
The isokinetic data of the present study is summarized in
Table I. The initial values for the maximum peak torque for
the extensors at angular velocities of 60°/s and 180°/s were
57±26.15 Nm and 32.33±19.63 Nm, respectively, in the
treatment group and 73.38±32.88/43.83±23.65 Nm in the
control group. The initial values for the maximum peak of
the flexor revealed a similar baseline difference between
treatment and control group (Table I).
The isokinetic peak torque (Nm) of the extensors and
flexors improved significantly (P<0.01) in the treatment
group (Figs 2 and 3). In the control group no change in the
isokinetic peak torque was found upon final evaluation.
Total work was defined as the work load at various
angular velocities (60°/s, 90°/s, 120°/s, 150°/s and 180°/s).
The initial values for the total work of the knee flexor and
extensor demonstrated a baseline difference between
treatment and control group.
The total work load documented in knee extension, as
well as knee flexion improved significantly following the
treatment with hyaluronic acid (P<0.01). Especially in knee
extension an increase of the total work (J) was noted. Thepreliminary value of 2046.28±1311.28 J improved to
3044.61±1539.23 J at the time of the follow-up evaluation.
In contrast, the parameters of the control group did not
improve during the evaluation period. The testing of the
knee flexors prior to treatment revealed values of
1310.39±1134.5 J and increased to 2034.22±1247.13 J
following the treatment with hyaluronic acid (Fig. 4).
The values for pain at rest prior to treatment documented
via VAS were found to be 3.67±1.53 cm for the controls
and 3.83±1.72 cm for the treatment group. During weight
bearing, the pain levels increased to 7.43±1.41 and
7.57±1.34, respectively. Upon conclusion of the treatment
protocol, pain at rest had decreased to 1.36±1.42 cm,
while the VAS level for pain upon weight bearing was found
to be 3.75±1.32 cm. These changes were found to be
significant (P<0.01) for the treated knees. The scores
for the control group did not change compared to the
preliminary results (Fig. 5).Fig. 1. Lequesne score (points).Table I
Peak torque (Nm)/angular velocities 60°/s and 180°/s (extension/flexion)
Treatment group Control group
60°/s 180°/s 60°/s 180°/s
Flexion
Before treatment 40.44±21.58 22.89±16.64 51.06±25.76 29.33±17.45
At follow-up 53.33±24.26 34.05±17.37 46.58±24.93 27.11±14.02
Extension
Before treatment 57±26.15 32.33±19.63 73.38±32.88 48.83±23.65
At follow-up 77.17±32.54 47.83±21.43 71.55±30.67 42.05±21.30Discussion
The goal of this study was to evaluate the effectiveness
of intraarticular hyaluronic acid with the help of functional
(isokinetic tests) and clinical parameters (Lequesne score,
pain levels) in patients with bilateral OA of the knee. In the
Osteoarthritis and Cartilage Vol. 10 No. 9 683Fig. 2. Maximum peak torque/extension (60°/s/180°/s).Fig. 3. Maximum peak torque/flexion (60°/s/180°/s).past, various studies with hyaluronic acid have also used
the Lequesne score to quantify joint function, while visual
analog scales (VAS) have proven to supply reliable data in
the documentation of pain levels21,22.
Pietrogrande was able to show a pain reduction 60 days
after the intraarticular administration of hyaluronic acid from
VAS values of 6 cm down to 2 cm9. The comparison of pain
upon weight bearing to that of the control groups showed a
significant difference after a period of 5 weeks23. Di Marco
and Letizia analysed pain upon weight bearing following
treatment with hyaluronic acid in 1995. They found a
reduction of the pain level from 6.7 cm to 4.7 cm24. Thedescribed improvement regarding pain at rest and during
weight bearing was also documented in our study.
The functional analysis as defined by Lequesne has in
past studies with hyaluronic documented improved scores
by about 4 points with a follow-up of one year11,23,25.
Lequesne defined effective treatment forms as those lead-
ing to a score improvement of 30–40% at the time of
follow-up26. In his study, the average patient with degen-
erative joint disease was described as presenting with
score values between 9–11 points. In our evaluation,
the treatment and control groups scored 13.57±1.88
and 12.48±1.68, respectively, at the time of the initial
684 O. Miltner et al.: Efficacy of intraarticular hyaluronic acid in patients with osteoarthritisFig. 4. Total work/extension/flexion.Fig. 5. Pain at rest/during weight bearing (VAS).examination. This documents that only patients with a high
level of disability were included in this study. The reduction
of the Lequesne score following treatment to 7.94±2.53
points represents an improvement of 40%, which is at the
upper end of the values used to define treatment effective-
ness. Therefore, using the Lequesne criteria, the intra-
articular administration of hyaluronic acid can be defined as
an effective therapeutic measure in the treatment of OA.
Isokinetic testing is frequently used to quantify muscle
weakness and dysbalances, as well as for the documen-
tation of therapeutic effects27–30. The comparison to the
untreated contralateral extremity represents a standardized
and well researched evaluation modus for such tests31–33.
Total work (J) and peak torque (Nm) have proven to bereliable parameters for the evaluation joint and muscle
function34. As part of a preliminary evaluation of 18
patients, it was possible to document the value of such
isokinetic testing. The study showed a significant improve-
ment of the total work in knee flexion, as well as knee
extension, following the treatment with hyaluronic acid35.
The fact that the more impaired knee was entered in the
treatment group more often than in the control group is
believed to be responsible for the difference of the baseline
values for total work (J) as well as peak torque (Nm) found
in this study. It must also be taken into account that more
patients with advanced radiographically documented joint
destruction (Kellgren III) are found in the treatment group
than in the control. In a previous study, Brandt described
Osteoarthritis and Cartilage Vol. 10 No. 9 685a similar correlation between radiographic changes and
muscle strength36.
In the present study, the total work load of the knee
flexors and extensors improved in the treatment group,
while the controls demonstrated a slight further muscle
weakening. Our study showed a significant improvement of
the maximum peak torque in extension and flexion at low
(60°/s), as well as high angular velocities (180°/s) (P<0.01)
following the injections. The application of hyaluronic acid
lead to an improvement of the parameters total work and
peak torque in the knees treated in this study.
The viscoelastic properties of the degenerative joint
are greatly reduced compared to normal conditions37. In an
in vitro study, Rainer described an increase in viscosity in
such pathological joint fluid by a factor of 8–10 following the
application of high molecular hyaluronic acid. An improve-
ment of the elastic qualities of the synovial fluid was also
documented, in turn leading to an improvement of the
biomechanics of the joint38.
The knee joint is supplied by three structurally and
functionally different afferent fibers39,40. These fibers
receive their signals from four different receptors (Pacinian,
Ruffini’s and Golgi-Mazzoni corpuscles; muscle spindles)
found in the tissues surrounding the joint. These receptors
vary in number and location41. The degenerative changes
in a joint lead to an increased release of a variety of
mediators resulting in a secondary stimulation of nocicep-
tors43,44. The interaction between the mechanoreceptors
and these nociceptors can lead to changes in coordinative
and muscular function of the affected extremity. The admin-
istration of intraarticular hyaluronic acid seems to reduce
this disabling effect, as evidenced by the increased
work load and peak torque secondary to the improved
neuromuscular function of the treated knees44,45.
One of the major factors leading to the improved joint
and muscle parameters is the reduction of pain both at rest
and during weight bearing. In 1992, Hayes and Falconer
evaluated 43 patients with OA and were able to show an
apparent weakening of the extensor, as well as flexor,
muscle groups46. Pain was defined as one of the major
causes of this muscle weakness47,48.
In conclusion it can be pointed out that the improvement
of the joint parameters can be explained by the improved
joint mechanics and muscular function, as well as the
reduced pain levels at rest and upon weight bearing.
With this pilot study, it was possible to demonstrate the
effectiveness of intraarticular administration of hyaluronic
acid with regard to functional (total work, peak torque) and
clinical parameters (Lequesne score, pain) in patients
suffering from OA. To evaluate the long-term effects of
hyaluronic acid, studies with longer follow-up periods will
be required.References
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